Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing

被引：0
作者：
Wei Li
Binglei Zhang
Weijie Cao
Wenli Zhang
Tiandong Li
Lina Liu
LinPing Xu
Fengcai Gao
Yanmei Wang
Fang Wang
Haizhou Xing
Zhongxing Jiang
Jianxiang Shi
Zhilei Bian
Yongping Song
机构：
[1] The First Affiliated Hospital of Zhengzhou University,Department of Hematology
[2] Henan Provincial Hematology Hospital,Department of Hematology
[3] Zhengzhou University,BGI College & Henan Institute of Medical and Pharmaceutical Sciences in Academy of Medical Science
[4] The Affiliated Cancer Hospital of Zhengzhou University,Department of Hematology
[5] Zhengzhou University,College of Public Health
[6] The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,Department of Research and Foreign Affairs
[7] Zhengzhou People’s Hospital,Department of Hematology
来源：
Experimental Hematology & Oncology | / 12卷
关键词：
BCMA CAR-T; Multiple myeloma; Resistant mechanisms; ScRNA-seq; T cell exhaustion; Monocyte/macrophages;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 502 条
[1]  
Siegel RL(2022)Cancer statistics, 2022 CA Cancer J Clin 72 7-33
[2]  
Miller KD(2021)Recent advances and discoveries in the mechanisms and functions of CAR T cells Nat Rev Cancer 21 145-161
[3]  
Fuchs HE(2021)CAR T cell therapies for patients with multiple myeloma Nat Rev Clin Oncol 18 71-84
[4]  
Jemal A(2020)Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia J Hematol Oncol 13 122-1659
[5]  
Larson RC(2021)Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL J Clin Oncol 39 1650-22
[6]  
Maus MV(2021)KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results Blood 138 11-335
[7]  
Mikkilineni L(2021)CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies J Hematol Oncol 14 26-3293
[8]  
Kochenderfer JN(2021)Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies Blood 137 323-2901
[9]  
Gu R(2021)A phase 1, multicenter study evaluating the safety and efficacy of KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma Am J Cancer Res 11 3285-1355
[10]  
Liu F(2021)A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma Blood 137 2890-7
12345678910